{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:16:23Z","timestamp":1788200183654,"version":"build-2803163510"},"reference-count":17,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T00:00:00Z","timestamp":1556755200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0598-9","type":"journal-article","created":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T12:05:52Z","timestamp":1556798752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4946-7926","authenticated-orcid":false,"given":"Roberta","family":"Noseda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaela","family":"Bertoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Ceschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,5,2]]},"reference":[{"key":"598_CR1","unstructured":"Henter JI, Elinder G. Ost a, and the the FHL study Group of the Histiocyte Society. Diagnostic guidelines for hemophagocytic lymphohistiocytosis. Semin Oncol. 1991;(1):29\u201333."},{"issue":"9927","key":"598_CR2","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/S0140-6736(13)61048-X","volume":"383","author":"M Ramos-Casals","year":"2014","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, L\u00f3pez-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014;383(9927):1503\u201316.","journal-title":"Lancet."},{"key":"598_CR3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158\u201368.","journal-title":"N Engl J Med"},{"key":"598_CR4","doi-asserted-by":"crossref","unstructured":"Daver N, Kantarjian H. Malignancy-associated haemophagocytic lymphohistiocytosis in adults. Lancet Oncol. 2017;(2):169\u201371.","DOI":"10.1016\/S1470-2045(17)30004-9"},{"issue":"6","key":"598_CR5","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1093\/annonc\/mdx113","volume":"28","author":"D Shah","year":"2017","unstructured":"Shah D, Shrestha R, Ramlal R, Hatton J, Saeed H. Pembrolizumab associated hemophagocytic lymphohistiocytosis. Ann Oncol. 2017;28(6):1403.","journal-title":"Ann Oncol"},{"issue":"1","key":"598_CR6","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/annonc\/mdw537","volume":"28","author":"M Takeshita","year":"2017","unstructured":"Takeshita M, Anai S, Mishima S, Inoue K. Coincidence of immunotherapy-associated hemophagocytic syndrome and rapid tumor regression. Ann Oncol. 2017;28(1):186\u20139.","journal-title":"Ann Oncol"},{"issue":"7","key":"598_CR7","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1093\/annonc\/mdy175","volume":"29","author":"K Sasaki","year":"2018","unstructured":"Sasaki K, Uehara J, Iinuma S, Doi H, Honma M, Toki Y, et al. Hemophagocytic lymphohistiocytosis associated with dabrafenib and trametinib combination therapy following pembrolizumab administration for advanced melanoma. Ann Oncol. 2018;29(7):1602\u20133.","journal-title":"Ann Oncol"},{"key":"598_CR8","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ejca.2018.01.063","volume":"93","author":"I Satzger","year":"2018","unstructured":"Satzger I, Ivanyi P, L\u00e4nger F, Kreipe HH, Schaper-Gerhardt K, Beutel G, et al. Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab. Eur J Cancer. 2018;93:150\u20133.","journal-title":"Eur J Cancer"},{"key":"598_CR9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ejca.2017.02.016","volume":"77","author":"N Malissen","year":"2017","unstructured":"Malissen N, Lacotte J, Du-Thanh A, Gaudy-Marqueste C, Guillot B, Grob JJ. Macrophage activation syndrome: a new complication of checkpoint inhibitors. Eur J Cancer. 2017;77:88\u20139.","journal-title":"Eur J Cancer"},{"issue":"1","key":"598_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40425-018-0365-3","volume":"6","author":"M Sadaat","year":"2018","unstructured":"Sadaat M, Jang S. Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report. J Immunother Cancer. 2018;6(1):49.","journal-title":"J Immunother Cancer."},{"issue":"2","key":"598_CR11","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1093\/annonc\/mdx701","volume":"29","author":"JM Michot","year":"2018","unstructured":"Michot JM, Pruvost R, Mateus C, Champiat S, Voisin AL, Marabelle A, et al. Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitors. Ann Oncol. 2018;29(2):518\u201320.","journal-title":"Ann Oncol"},{"issue":"1","key":"598_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s40425-018-0384-0","volume":"6","author":"A Hantel","year":"2018","unstructured":"Hantel A, Gabster B, Chenj JX, Golomb H, Gajewski TF. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab. J Immunother Cancer. 2018;6(1):73.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"598_CR13","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","volume":"42","author":"M Lindquist","year":"2008","unstructured":"Lindquist M. VigiBase, the WHO global ICSR database system: basic facts. Drug Inf J. 2008;42(5):409\u201319.","journal-title":"Drug Inf J"},{"key":"598_CR14","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/eji.201646686","volume":"47","author":"S Ammann","year":"2017","unstructured":"Ammann S, Lehmberg K, Zur Stadt U, Janka G, Rensing-Ehl A, Klemann C, et al. Primary and secondary hemophagocytic lymphohistiocytosis have different patterns of T-cell activation, differentiation and repertoire. Eur J Immunol. 2017;47:364\u201373.","journal-title":"Eur J Immunol"},{"key":"598_CR15","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S0002-9343(02)01035-5","volume":"112","author":"O Lambotte","year":"2002","unstructured":"Lambotte O, Costedoat-Chalumeau N, Amoura Z, Piette JC, Cacoub P. Drug-induced hemophagocytosis. Am J Med. 2002;112:592\u20133.","journal-title":"Am J Med"},{"key":"598_CR16","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.pediatrneurol.2003.12.012","volume":"30","author":"YC Yang","year":"2004","unstructured":"Yang YC, Jou ST, Chang YH, Liang JS, Lee WT. Hemophagocytic syndrome associated with antiepileptic drug. Pediatr Neurol. 2004;30:358\u201360.","journal-title":"Pediatr Neurol"},{"issue":"3","key":"598_CR17","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.lpm.2015.12.004","volume":"45","author":"G Lakhoua","year":"2016","unstructured":"Lakhoua G, Aouinti I, Sahnoun R, Kastalli S, Daghfous R, Za\u00efem A. A hemophagocytosis syndrome attributed to phenobarbital. Presse Med. 2016;45(3):379\u201381.","journal-title":"Presse Med"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0598-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0598-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0598-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T18:09:36Z","timestamp":1607537376000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0598-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,2]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["598"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0598-9","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,2]]},"assertion":[{"value":"13 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was not required according to the Swiss Human Research Act (no intervention with human subjects or access to identifiable information).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.Study results and conclusions are those of the authors and do not necessarily represent the opinion of the WHO.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"117"}}